EX-99.SECTION 19(A) 4 tm2225213d1_ex99-section19a.htm EXHIBIT 99.SECTION 19(A)

 

Exhibit 99.Section 19(a)

 

EXHIBIT 4: SECTION 19(a) NOTICE TO FUND’S SHAREHOLDERS

 

TEKLA LIFE SCIENCES INVESTORS

 

Notification of Sources of Distribution

 

Distribution Paid Date: June 30, 2022

 

Distribution Amount Per Common Share: $0.35

 

The following table sets forth the estimated amounts of the current distribution, paid June 30, 2022, and the cumulative distributions paid this fiscal year-to-date from the following sources: net investment income, net realized short-term capital gains, net realized long-term capital gains and return of capital or other capital source. The Fund estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of your distribution may be a return of capital. A return of capital may occur, for example, when some or all the money that you invested in the Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund's investment performance and should not be confused with ‘yield’ or ‘income’. All amounts are expressed per common share.

 

               Percentage 
       Percentage      Breakdown of the 
       Breakdown   Total Cumulative   Total Cumulative 
   Current   of Current   Distributions for the   Distributions for the 
   Distribution   Distribution   Fiscal Year to Date1   Fiscal Year to Date1 
Net Investment Income  $0.0000    0%  $0.0000    0%
Net Realized ST Cap Gains  $0.0000    0%  $0.0342    3%
Net Realized LT Cap Gains  $0.0544    16%  $0.5962    51%
Return of Capital or Other Capital Source  $0.2956    84%  $0.5296    46%
TOTAL (per common share):  $0.3500    100%  $1.1600    100%

 

The table below includes information relating to the Fund’s performance based on its NAV for certain periods.

 

Average annual total return at NAV for the period from April 30, 2017 through April 30, 2022   3.22%
Annualized current distribution rate expressed as a percentage of NAV as of April 30, 2022   8.83%
Cumulative total return at NAV for the fiscal year, through April 30, 20222   -21.84%
Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of April 30, 20221   7.32%

 

You should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s managed distribution policy.

 

The composition of this and subsequent distribution may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $27,738,231, of which $20,963,340 represents net unrealized appreciation of portfolio securities.

 

The amounts and sources of distributions reported in this 19(a) Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

 

1The Fund’s current fiscal year began on October 1, 2021.
2Cumulative total return at NAV is the percentage change in the Fund’s NAV and includes all distributions and assumes the reinvestment of those distributions for the period of September 30, 2021 through April 30, 2022.

 

Tekla Life Sciences Investors

CUSIP: 87911K100

www.teklacap.com

 

Tekla Capital Management LLC

100 Federal Street, 19th Floor

Boston, Massachusetts 02110

 

617-772-8500
Fax: 617-772-8577

 

03NXXA       002CSND064

 

 

 

 

TEKLA LIFE SCIENCES INVESTORS

 

Notification of Sources of Distribution

 

Distribution Paid Date: September 30, 2022

 

Distribution Amount Per Common Share: $0.31

 

The following table sets forth the estimated amounts of the current distribution, paid September 30, 2022, and the cumulative distributions paid this fiscal year-to-date from the following sources: net investment income, net realized short-term capital gains, net realized long-term capital gains and return of capital or other capital source. The Fund estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of your distribution may be a return of capital. A return of capital may occur, for example, when some or all the money that you invested in the Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund's investment performance and should not be confused with ‘yield’ or ‘income’. All amounts are expressed per common share.

 

               Percentage 
       Percentage      Breakdown of the 
       Breakdown   Total Cumulative   Total Cumulative 
   Current   of Current   Distributions for the   Distributions for the 
   Distribution   Distribution   Fiscal Year to Date1   Fiscal Year to Date1 
Net Investment Income  $0.0000    0%  $0.0000    0%
Net Realized ST Cap Gains  $0.0000    0%  $0.0342    2%
Net Realized LT Cap Gains  $0.3100    100%  $0.9062    62%
Return of Capital or Other Capital Source  $0.0000    0%  $0.5296    36%
TOTAL (per common share):  $0.3100    100%  $1.4700    100%

 

The table below includes information relating to the Fund’s performance based on its NAV for certain periods.

 

Average annual total return at NAV for the period from July 31, 2017 through July 31, 2022   3.12%
Annualized current distribution rate expressed as a percentage of NAV as of July 31, 2022   7.69%
Cumulative total return at NAV for the fiscal year, through July 31, 20222   -18.46%
Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of July 31, 20221   9.11%

 

You should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s managed distribution policy.

 

The composition of this and subsequent distribution may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $44,467,697, of which $16,672,970 represents net unrealized appreciation of portfolio securities.

 

The amounts and sources of distributions reported in this 19(a) Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

 

1The Fund’s current fiscal year began on October 1, 2021.

2Cumulative total return at NAV is the percentage change in the Fund’s NAV and includes all distributions and assumes the reinvestment of those distributions for the period of September 30, 2021 through July 31, 2022.

 

Tekla Life Sciences Investors

CUSIP: 87911K100

www.teklacap.com

 

Tekla Capital Management LLC

100 Federal Street, 19th Floor

Boston, Massachusetts 02110

 

617-772-8500

Fax: 617-772-8577

 

03P61A        002CSND32A